BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takagi M, Shinoda K, Piao J, Mitsuiki N, Takagi M, Matsuda K, Muramatsu H, Doisaki S, Nagasawa M, Morio T, Kasahara Y, Koike K, Kojima S, Takao A, Mizutani S. Autoimmune lymphoproliferative syndrome–like disease with somatic KRAS mutation. Blood 2011;117:2887-90. [DOI: 10.1182/blood-2010-08-301515] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Lanzarotti N, Bruneau J, Trinquand A, Stolzenberg M, Neven B, Fregeac J, Levy E, Jeremiah N, Suarez F, Mahlaoui N, Fischer A, Magerus-chatinet A, Cavé H, Rieux-laucat F. RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. Blood 2014;123:1960-3. [DOI: 10.1182/blood-2014-01-548958] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
2 Madkaikar M, Mhatre S, Gupta M, Ghosh K. Advances in autoimmune lymphoproliferative syndromes: ALPS. European Journal of Haematology 2011;87:1-9. [DOI: 10.1111/j.1600-0609.2011.01617.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
3 Aluri J, Cooper MA. Genetic Mosaicism as a Cause of Inborn Errors of Immunity. J Clin Immunol 2021;41:718-28. [PMID: 33864184 DOI: 10.1007/s10875-021-01037-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gruber C, Bogunovic D. Incomplete penetrance in primary immunodeficiency: a skeleton in the closet. Hum Genet 2020;139:745-57. [PMID: 32067110 DOI: 10.1007/s00439-020-02131-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
5 Yanir AD, Krauss A, Stein J, Steinberg-Shemer O, Gilad O, Lotan SN, Dgany O, Krasnov T, Kodman Y, Feuerstein T, Mardoukh J, Fishman H, Geron I, Yacobovich J, Tamary H, Birger Y, Avrahami G, Izraeli S, Birenboim SB. Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome. Pediatr Blood Cancer 2021;68:e29138. [PMID: 34019335 DOI: 10.1002/pbc.29138] [Reference Citation Analysis]
6 Levy-Mendelovich S, Lev A, Rechavi E, Barel O, Golan H, Bielorai B, Neumann Y, Simon AJ, Somech R. T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing. Clin Exp Immunol 2017;189:310-7. [PMID: 28500641 DOI: 10.1111/cei.12986] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
7 Kothari A, Hulbert ML, Cottrell CE, Nguyen TT. Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication. Leuk Lymphoma 2015;56:1175-8. [PMID: 25110823 DOI: 10.3109/10428194.2014.953152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Greenmyer JR, Kohorst M. Pediatric Neoplasms Presenting with Monocytosis. Curr Hematol Malig Rep 2021;16:235-46. [PMID: 33630234 DOI: 10.1007/s11899-021-00611-x] [Reference Citation Analysis]
9 Saifi M, Wysocki CA. Autoimmune Disease in Primary Immunodeficiency. Immunology and Allergy Clinics of North America 2015;35:731-52. [DOI: 10.1016/j.iac.2015.07.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
10 Maschan M, Bobrynina V, Khachatryan L, Kalinina I, Solopova G, Avdonin P, Nasedkina T, Novichkova G, Maschan A. Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation. Pediatr Blood Cancer 2014;61:1871-3. [PMID: 24590757 DOI: 10.1002/pbc.25013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Zhang J, Barbaro P, Guo Y, Alodaib A, Li J, Gold W, Adès L, Keating BJ, Xu X, Teo J, Hakonarson H, Christodoulou J. Utility of next-generation sequencing technologies for the efficient genetic resolution of haematological disorders. Clin Genet 2016;89:163-72. [PMID: 25703294 DOI: 10.1111/cge.12573] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kubara K, Yamazaki K, Ishihara Y, Naruto T, Lin HT, Nishimura K, Ohtaka M, Nakanishi M, Ito M, Tsukahara K, Morio T, Takagi M, Otsu M. Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity. Stem Cell Reports 2018;11:380-94. [PMID: 29983389 DOI: 10.1016/j.stemcr.2018.06.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
13 Shannon K, Li Q. Oncogenic Ras scales the ALPS. Blood 2011;117:2747-8. [DOI: 10.1182/blood-2010-12-320721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Messina S. Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis. Small GTPases 2020;11:312-9. [PMID: 30043672 DOI: 10.1080/21541248.2018.1502591] [Reference Citation Analysis]
15 Takagi M, Piao J, Lin L, Kawaguchi H, Imai C, Ogawa A, Watanabe A, Akiyama K, Kobayashi C, Mori M, Ko K, Sugimoto M, Mizutani S. Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML. Leukemia 2013;27:1926-8. [DOI: 10.1038/leu.2013.82] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chan LN, Müschen M. B-cell identity as a metabolic barrier against malignant transformation. Exp Hematol 2017;53:1-6. [PMID: 28655536 DOI: 10.1016/j.exphem.2017.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
17 Aoki Y, Matsubara Y. Ras/MAPK syndromes and childhood hemato-oncological diseases. Int J Hematol 2013;97:30-6. [PMID: 23250860 DOI: 10.1007/s12185-012-1239-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
18 Hanaya A, Miyamae T, Kishi T, Sahara M, Tani Y, Yamanaka H, Nagata S. Systemic lupus erythematosus associated with RASopathy. Modern Rheumatology Case Reports 2017;1:94-8. [DOI: 10.1080/24725625.2017.1337310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Gratzinger D, Jaffe ES, Chadburn A, Chan JK, de Jong D, Goodlad JR, Said J, Natkunam Y. Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 5. Am J Clin Pathol 2017;147:204-16. [PMID: 28395106 DOI: 10.1093/ajcp/aqw215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
20 Van Horebeek L, Dubois B, Goris A. Somatic Variants: New Kids on the Block in Human Immunogenetics. Trends Genet 2019;35:935-47. [PMID: 31668909 DOI: 10.1016/j.tig.2019.09.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
21 Nabhani S, Ginzel S, Miskin H, Revel-Vilk S, Harlev D, Fleckenstein B, Hönscheid A, Oommen PT, Kuhlen M, Thiele R, Laws HJ, Borkhardt A, Stepensky P, Fischer U. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease. Haematologica 2015;100:1189-98. [PMID: 26113417 DOI: 10.3324/haematol.2014.114967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Li P, Huang P, Yang Y, Hao M, Peng H, Li F. Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). Clin Rev Allergy Immunol 2016;50:55-63. [PMID: 25663566 DOI: 10.1007/s12016-015-8466-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
23 Rensing-Ehl A, Janda A, Lorenz MR, Gladstone BP, Fuchs I, Abinun M, Albert M, Butler K, Cant A, Cseh AM, Ebinger M, Goldacker S, Hambleton S, Hebart H, Houet L, Kentouche K, Kühnle I, Lehmberg K, Mejstrikova E, Niemeyer C, Minkov M, Neth O, Dückers G, Owens S, Rösler J, Schilling FH, Schuster V, Seidel MG, Smisek P, Sukova M, Svec P, Wiesel T, Gathmann B, Schwarz K, Vach W, Ehl S, Speckmann C. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia. Haematologica 2013;98:1948-55. [PMID: 23850805 DOI: 10.3324/haematol.2012.081901] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
24 Papa R, Rusmini M, Schena F, Traggiai E, Coccia MC, Caorsi R, Arrigo S, Pasetti F, Signa S, Barone P, Santamaria G, Spirito G, Sanges R, Vozzi D, Cavalli A, Gustincich S, Ravelli A, Gattorno M, Ceccherini I, Volpi S. Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD). Clin Immunol 2021;231:108837. [PMID: 34455097 DOI: 10.1016/j.clim.2021.108837] [Reference Citation Analysis]
25 Neven Q, Boulanger C, Bruwier A, de Ville de Goyet M, Meyts I, Moens L, Van Damme A, Brichard B. Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD). J Clin Immunol 2021;41:51-8. [PMID: 33011939 DOI: 10.1007/s10875-020-00883-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 George LA, Teachey DT. Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children. Pediatr Drugs 2016;18:261-72. [DOI: 10.1007/s40272-016-0175-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
27 Niemeyer CM, Flotho C. Juvenile myelomonocytic leukemia: who's the driver at the wheel? Blood 2019;133:1060-70. [PMID: 30670449 DOI: 10.1182/blood-2018-11-844688] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
28 Hadjadj J, Aladjidi N, Fernandes H, Leverger G, Magérus-Chatinet A, Mazerolles F, Stolzenberg MC, Jacques S, Picard C, Rosain J, Fourrage C, Hanein S, Zarhrate M, Pasquet M, Abou Chahla W, Barlogis V, Bertrand Y, Pellier I, Colomb Bottollier E, Fouyssac F, Blouin P, Thomas C, Cheikh N, Dore E, Pondarre C, Plantaz D, Jeziorski E, Millot F, Garcelon N, Ducassou S, Perel Y, Leblanc T, Neven B, Fischer A, Rieux-Laucat F; members of the French Reference Center for Pediatric Autoimmune Cytopenia (CEREVANCE). Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood 2019;134:9-21. [PMID: 30940614 DOI: 10.1182/blood-2018-11-887141] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 14.7] [Reference Citation Analysis]
29 López-Nevado M, González-Granado LI, Ruiz-García R, Pleguezuelo D, Cabrera-Marante O, Salmón N, Blanco-Lobo P, Domínguez-Pinilla N, Rodríguez-Pena R, Sebastián E, Cruz-Rojo J, Olbrich P, Ruiz-Contreras J, Paz-Artal E, Neth O, Allende LM. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. Front Immunol 2021;12:671755. [PMID: 34447369 DOI: 10.3389/fimmu.2021.671755] [Reference Citation Analysis]
30 Leung ELH, Luo LX, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ, Ward DC, Liu L. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death Dis 2018;9:216. [PMID: 29440631 DOI: 10.1038/s41419-017-0065-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
31 Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood 2011;118:5741-51. [PMID: 21885601 DOI: 10.1182/blood-2011-07-325217] [Cited by in Crossref: 108] [Cited by in F6Publishing: 74] [Article Influence: 9.8] [Reference Citation Analysis]
32 Mao H, Yang W, Latour S, Yang J, Winter S, Zheng J, Ni K, Lv M, Liu C, Huang H, Chan K, Pui-wah Lee P, Tu W, Fischer A, Lau Y. RASGRP1 mutation in autoimmune lymphoproliferative syndrome-like disease. Journal of Allergy and Clinical Immunology 2018;142:595-604.e16. [DOI: 10.1016/j.jaci.2017.10.026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
33 Yoshida N, Doisaki S, Kojima S. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations. Paediatr Drugs 2012;14:157-63. [PMID: 22480363 DOI: 10.2165/11631360-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
34 Wang W, Zhou Y, Zhong L, Wang L, Tang X, Ma M, Li J, Song H. RAS-associated Autoimmune Leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children. Pediatr Rheumatol Online J 2019;17:55. [PMID: 31412876 DOI: 10.1186/s12969-019-0346-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Oliveira JB. The expanding spectrum of the autoimmune lymphoproliferative syndromes. Curr Opin Pediatr 2013;25:722-9. [PMID: 24240292 DOI: 10.1097/MOP.0000000000000032] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
36 Okano T, Imai K, Naruto T, Okada S, Yamashita M, Yeh TW, Ono S, Tanaka K, Okamoto K, Tanita K, Matsumoto K, Toyofuku E, Kumaki-Matsumoto E, Okamura M, Ueno H, Ogawa S, Ohara O, Takagi M, Kanegane H, Morio T. Whole-Exome Sequencing-Based Approach for Germline Mutations in Patients with Inborn Errors of Immunity. J Clin Immunol 2020;40:729-40. [PMID: 32506361 DOI: 10.1007/s10875-020-00798-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
37 Seleman M, Hoyos-Bachiloglu R, Geha RS, Chou J. Uses of Next-Generation Sequencing Technologies for the Diagnosis of Primary Immunodeficiencies. Front Immunol 2017;8:847. [PMID: 28791010 DOI: 10.3389/fimmu.2017.00847] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
38 Lachenaud J, Strullu M, Baruchel A, Cavé H. Les leucémies myélomonocytaires juvéniles. Bulletin du Cancer 2014;101:302-13. [DOI: 10.1684/bdc.2014.1908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 McConnell MJ, Moran JV, Abyzov A, Akbarian S, Bae T, Cortes-Ciriano I, Erwin JA, Fasching L, Flasch DA, Freed D, Ganz J, Jaffe AE, Kwan KY, Kwon M, Lodato MA, Mills RE, Paquola ACM, Rodin RE, Rosenbluh C, Sestan N, Sherman MA, Shin JH, Song S, Straub RE, Thorpe J, Weinberger DR, Urban AE, Zhou B, Gage FH, Lehner T, Senthil G, Walsh CA, Chess A, Courchesne E, Gleeson JG, Kidd JM, Park PJ, Pevsner J, Vaccarino FM; Brain Somatic Mosaicism Network. Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network. Science 2017;356:eaal1641. [PMID: 28450582 DOI: 10.1126/science.aal1641] [Cited by in Crossref: 146] [Cited by in F6Publishing: 115] [Article Influence: 29.2] [Reference Citation Analysis]
40 Tran TAN, Grow WB, Chang C. Superficial and Deep Cutaneous Involvement by RAS-Associated Autoimmunne Leukoproliferative Disease (RALD Cutis): A Histologic Mimicker of Histiocytoid Sweet Syndrome. The American Journal of Dermatopathology 2019;41:606-10. [DOI: 10.1097/dad.0000000000001332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
41 Takagi M, Ogata S, Ueno H, Yoshida K, Yeh T, Hoshino A, Piao J, Yamashita M, Nanya M, Okano T, Kajiwara M, Kanegane H, Muramatsu H, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Bando Y, Kato M, Hayashi Y, Miyano S, Imai K, Ogawa S, Kojima S, Morio T. Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 2017;139:1914-22. [PMID: 27845235 DOI: 10.1016/j.jaci.2016.09.038] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 10.5] [Reference Citation Analysis]
42 Plander M, Kalman B. Rare autoimmune disorders with Mendelian inheritance. Autoimmunity 2016;49:285-97. [PMID: 27207228 DOI: 10.1080/08916934.2016.1183658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
43 Besnard C, Levy E, Aladjidi N, Stolzenberg MC, Magerus-Chatinet A, Alibeu O, Nitschke P, Blanche S, Hermine O, Jeziorski E, Landman-Parker J, Leverger G, Mahlaoui N, Michel G, Pellier I, Suarez F, Thuret I, de Saint-Basile G, Picard C, Fischer A, Neven B, Rieux-Laucat F, Quartier P;  Members of the French reference center for pediatric autoimmune cytopenias (CEREVANCE). Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clin Immunol. 2018;188:52-57. [PMID: 29330115 DOI: 10.1016/j.clim.2017.12.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
44 Müschen M. Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation. Nat Rev Immunol 2019;19:337-48. [DOI: 10.1038/s41577-019-0154-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
45 Comrie WA, Lenardo MJ. Molecular Classification of Primary Immunodeficiencies of T Lymphocytes. Adv Immunol 2018;138:99-193. [PMID: 29731008 DOI: 10.1016/bs.ai.2018.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Tüfekçi Ö, Ören H, Demir Yenigürbüz F, Gözmen S, Karapınar TH, İrken G. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features. Turk J Haematol 2015;32:175-9. [PMID: 26316488 DOI: 10.4274/tjh.2014.0034] [Reference Citation Analysis]
47 Blanchard-Rohner G, Ragotte RJ, Junker AK, Sharma M, Del Bel KL, Lu HY, Erdle S, Chomyn A, Gill H, Tucker LB, Schreiber RA, Rozmus J, Biggs CM, Hildebrand KJ, Wu J, Stockler-Ipsiroglu S, Turvey SE. Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report. BMC Pediatr 2021;21:45. [PMID: 33472608 DOI: 10.1186/s12887-021-02508-3] [Reference Citation Analysis]
48 Chang TY, Dvorak CC, Loh ML. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood 2014;124:2487-97. [PMID: 25163700 DOI: 10.1182/blood-2014-03-300319] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
49 Peacock JD, Dykema KJ, Toriello HV, Mooney MR, Scholten DJ, Winn ME, Borgman A, Duesbery NS, Hiemenga JA, Liu C, Campbell S, Nickoloff BP, Williams BO, Steensma M. Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. Am J Med Genet 2015;167:1429-35. [DOI: 10.1002/ajmg.a.37048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
50 Fleisher TA, Oliveira JB. Monogenic defects in lymphocyte apoptosis. Curr Opin Allergy Clin Immunol 2012;12:609-15. [PMID: 22918222 DOI: 10.1097/ACI.0b013e3283588da0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
51 Bader-Meunier B, Cavé H, Jeremiah N, Magerus A, Lanzarotti N, Rieux-Laucat F, Cormier-Daire V. Are RASopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum 2013;43:217-9. [PMID: 23786871 DOI: 10.1016/j.semarthrit.2013.04.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
52 Chandrakasan S, Chandra S, Davila Saldana BJ, Torgerson TR, Buchbinder D. Primary immune regulatory disorders for the pediatric hematologist and oncologist: A case‐based review. Pediatr Blood Cancer 2019;66:e27619. [DOI: 10.1002/pbc.27619] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
53 Miyazaki Y. Guest editorial: introduction of Progress in Hematology in this issue. Int J Hematol 2012;95:5-7. [PMID: 22231992 DOI: 10.1007/s12185-011-0998-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Meynier S, Rieux-Laucat F. After 95 years, it's time to eRASe JMML. Blood Rev 2020;43:100652. [PMID: 31980238 DOI: 10.1016/j.blre.2020.100652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
55 van der Werff ten Bosch J, van den Akker M. Genetic predisposition and hematopoietic malignancies in children: Primary immunodeficiency. European Journal of Medical Genetics 2016;59:647-53. [DOI: 10.1016/j.ejmg.2016.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
56 Jun JE, Rubio I, Roose JP. Regulation of ras exchange factors and cellular localization of ras activation by lipid messengers in T cells. Front Immunol 2013;4:239. [PMID: 24027568 DOI: 10.3389/fimmu.2013.00239] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
57 Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: An expanding universe. Sci Immunol 2020;5:eabb1662. [PMID: 32651211 DOI: 10.1126/sciimmunol.abb1662] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
58 Detanico T, St Clair JB, Aviszus K, Kirchenbaum G, Guo W, Wysocki LJ. Somatic mutagenesis in autoimmunity. Autoimmunity 2013;46:102-14. [PMID: 23249093 DOI: 10.3109/08916934.2012.757597] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
59 Rivas-larrauri F, Yamazaki-nakashimada MA. Lupus eritematoso sistémico: ¿es una sola enfermedad? Reumatología Clínica 2016;12:274-81. [DOI: 10.1016/j.reuma.2016.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
60 Sharifinejad N, Azizi G, Behniafard N, Zaki-Dizaji M, Jamee M, Yazdani R, Abolhassani H, Aghamohammadi A. Protein Kinase C-Delta Defect in Autoimmune Lymphoproliferative Syndrome-Like Disease: First Case from the National Iranian Registry and Review of the Literature. Immunol Invest 2020;:1-12. [PMID: 33047643 DOI: 10.1080/08820139.2020.1829638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Li G, Li Y, Liu H, Shi Y, Guan W, Zhang T, Yao W, Wu B, Xu H, Sun L. Genetic heterogeneity of pediatric systemic lupus erythematosus with lymphoproliferation. Medicine (Baltimore) 2020;99:e20232. [PMID: 32443356 DOI: 10.1097/MD.0000000000020232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Meynier S, Rieux-Laucat F. FAS and RAS related Apoptosis defects: From autoimmunity to leukemia. Immunol Rev 2019;287:50-61. [PMID: 30565243 DOI: 10.1111/imr.12720] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
63 Toyoda H, Deguchi T, Iwamoto S, Kihira K, Hori H, Komada Y, Hirayama M. Weekly Rituximab Followed by Monthly Rituximab Treatment for Autoimmune Disease Associated With RAS-associated Autoimmune Leukoproliferative Disease. Journal of Pediatric Hematology/Oncology 2018;40:e516-8. [DOI: 10.1097/mph.0000000000001276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 Niemeyer CM. RAS diseases in children. Haematologica 2014;99:1653-62. [PMID: 25420281 DOI: 10.3324/haematol.2014.114595] [Cited by in Crossref: 78] [Cited by in F6Publishing: 60] [Article Influence: 11.1] [Reference Citation Analysis]
65 Chang CA, Perrier R, Kurek KC, Estrada-Veras J, Lehman A, Yip S, Hendson G, Diamond C, Pinchot JW, Tran JM, Arkin LM, Drolet BA, Napier MP, O'Neill SA, Balci TB, Keppler-Noreuil KM. Novel findings and expansion of phenotype in a mosaic RASopathy caused by somatic KRAS variants. Am J Med Genet A 2021;185:2829-45. [PMID: 34056834 DOI: 10.1002/ajmg.a.62356] [Reference Citation Analysis]
66 Millrine D, Tei M, Gemechu Y, Kishimoto T. Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production. Proc Natl Acad Sci U S A 2016;113:10625-30. [PMID: 27601648 DOI: 10.1073/pnas.1611751113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
67 Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer 2017;17:425-40. [PMID: 28642604 DOI: 10.1038/nrc.2017.40] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
68 Sikora KA, Wells K, Bolek EC, Jones AI, Grayson PC. Somatic Mutations in Rheumatologic Diseases: VEXAS Syndrome and Beyond. Rheumatology (Oxford) 2021:keab868. [PMID: 34888629 DOI: 10.1093/rheumatology/keab868] [Reference Citation Analysis]
69 Neven B, Magerus-chatinet A, Florkin B, Gobert D, Lambotte O, De Somer L, Lanzarotti N, Stolzenberg M, Bader-meunier B, Aladjidi N, Chantrain C, Bertrand Y, Jeziorski E, Leverger G, Michel G, Suarez F, Oksenhendler E, Hermine O, Blanche S, Picard C, Fischer A, Rieux-laucat F. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011;118:4798-807. [DOI: 10.1182/blood-2011-04-347641] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 9.4] [Reference Citation Analysis]
70 Shive HR, West RR, Embree LJ, Sexton JM, Hickstein DD. Expression of KRASG12V in Zebrafish Gills Induces Hyperplasia and CXCL8-Associated Inflammation. Zebrafish 2015;12:221-9. [PMID: 25798815 DOI: 10.1089/zeb.2014.1038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
71 Riller Q, Rieux-Laucat F. RASopathies: from germline mutations to somatic and multigenic diseases. Biomed J 2021:S2319-4170(21)00070-6. [PMID: 34175492 DOI: 10.1016/j.bj.2021.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Giacaman A, Bauzá Alonso A, Salinas Sanz JA, Dapena Díaz JL, Ramos Asensio R, Ferrés Ramis L, Durán Pastor MA, Martín-santiago A. Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD). Clin Exp Dermatol 2018;43:913-6. [DOI: 10.1111/ced.13668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
73 Takagi M, Hoshino A, Yoshida K, Ueno H, Imai K, Piao J, Kanegane H, Yamashita M, Okano T, Muramatsu H, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Hayashi Y, Kojima S, Morio T. Genetic heterogeneity of uncharacterized childhood autoimmune diseases with lymphoproliferation. Pediatr Blood Cancer 2018;65:e26831. [DOI: 10.1002/pbc.26831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
74 Uehara T, Hosogaya N, Matsuo N, Kosaki K. Systemic lupus erythematosus in a patient with Noonan syndrome-like disorder with loose anagen hair 1: More than a chance association. Am J Med Genet A 2018;176:1662-6. [PMID: 29737035 DOI: 10.1002/ajmg.a.38834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
75 Calvo KR, Price S, Braylan RC, Oliveira JB, Lenardo M, Fleisher TA, Rao VK. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood 2015;125:2753-8. [PMID: 25691160 DOI: 10.1182/blood-2014-11-567917] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
76 Singh A, Jindal AK, Joshi V, Anjani G, Rawat A. An updated review on phenocopies of primary immunodeficiency diseases. Genes Dis 2020;7:12-25. [PMID: 32181272 DOI: 10.1016/j.gendis.2019.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
77 Sakashita K, Matsuda K, Koike K. Diagnosis and treatment of juvenile myelomonocytic leukemia. Pediatrics International 2016;58:681-90. [DOI: 10.1111/ped.13068] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
78 Garrido Colino C. [Advances in the knowledge and management of autoimmune lymphoproliferative syndrome]. An Pediatr (Barc) 2014;80:122.e1-7. [PMID: 24055319 DOI: 10.1016/j.anpedi.2013.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Shiota M, Yang X, Kubokawa M, Morishima T, Tanaka K, Mikami M, Yoshida K, Kikuchi M, Izawa K, Nishikomori R, Okuno Y, Wang X, Sakaguchi H, Muramatsu H, Kojima S, Miyano S, Ogawa S, Takagi M, Hata D, Kanegane H. Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases. J Clin Immunol 2015;35:454-8. [PMID: 25896945 DOI: 10.1007/s10875-015-0163-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
80 Flotho C. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia. Epigenetics 2019;14:236-44. [PMID: 30773984 DOI: 10.1080/15592294.2019.1583039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Niss O, Sholl A, Bleesing JJ, Hildeman DA. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 2015;135:762-70. [PMID: 25174872 DOI: 10.1016/j.jaci.2014.07.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
82 Teachey DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 2012;24:1-8. [PMID: 22157362 DOI: 10.1097/MOP.0b013e32834ea739] [Cited by in Crossref: 73] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
83 Rieux-laucat F. What's up in the ALPS. Current Opinion in Immunology 2017;49:79-86. [DOI: 10.1016/j.coi.2017.10.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
84 Azizi G, Pouyani MR, Abolhassani H, Sharifi L, dizaji MZ, Mohammadi J, Mirshafiey A, Aghamohammadi A. Cellular and molecular mechanisms of immune dysregulation and autoimmunity. Cellular Immunology 2016;310:14-26. [DOI: 10.1016/j.cellimm.2016.08.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]